✦ LIBER ✦

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

✍ Scribed by Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbauer; Aron Goldhirsch; Michael Untch; Ian Smith; José Baselga; Christian Jackisch; David Cameron; Max Mano; José Luiz Pedrini; Andrea Veronesi; Cesar Mendiola; Anna Pluzanska; Vladimir Semiglazov; Eduard Vrdoljak; Michael J Eckart; Zhenzhou Shen; George Skiadopoulos; Marion Procter; Kathleen I Pritchard; Martine J Piccart-Gebhart; Richard Bell

Book ID: 117785590
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 322 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70033-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2-year follow-up of trastuzumab after ad

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

✍ Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyerei 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB

Neoadjuvant chemotherapy with trastuzuma

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 124 KB

Two years of adjuvant tamoxifen in preme

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up

✍ Lisa Rydén; Per-Ebbe Jönsson; Gunilla Chebil; Monika Dufmats; Mårten Fernö; Kari 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Trastuzumab in combination with chemothe

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

✍ Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Aki 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 332 KB

Long-term effect of trastuzumab on QT di

Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study

✍ Ozgur Tanriverdi, Nezih Meydan, Sabri Barutca 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 179 KB

A pilot study of adjuvant nanoparticle a

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

✍ Denise Yardley; Howard Burris; Nancy Peacock; Eric Raefsky; Marianne Melnik; Rog 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 171 KB